JAC Advance Access originally published online on January 12, 2006
Journal of Antimicrobial Chemotherapy 2006 57(3):498-505; doi:10.1093/jac/dki489
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation
1 Clinical Microbiology—MTC, Karolinska Institute, Karolinska Hospital L2:02, 17176 Stockholm, Sweden; 2 Clinical Microbiology, Malmö University Hospital, Malmö, Sweden; 3 Department of Infectious Diseases, Karolinska Hospital, Karolinska Institute, SE-17176 Stockholm, Sweden; 4 Division of Clinical Microbiology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, SE-58185 Linköping, Sweden
Received 24 September 2005; returned 9 November 2005; revised 14 December 2005; accepted 20 December 2005
* Corresponding author. Tel: +46-8-51774910; Fax: +46-8-308099; E-mail: goran.kronvall{at}ki.se
Objectives: To apply the normalized resistance interpretation (NRI) method to Etest MIC results which have higher precision than conventional log2 dilution MIC tests due to the inclusion of intermediate values. If successful, NRI might provide an objective tool for the definition of epidemiological MIC cut-off values.
Methods: MICs of tigecycline and other antimicrobial agents were determined for 4771 clinical isolates comprising five Gram-positive and 13 Gram-negative species or species groups using the Etest. Histograms of MIC values were constructed for each species and NRI calculations were applied to them. An upper MIC limit of 2.5 SD above the theoretical mean of the normalized distribution was used for setting the epidemiological cut-off values.
Results: Calculated cut-off values for wild-type strains were between 0.11 and 0.96 mg/L for Gram-positive species, and between 0.44 and 8.3 mg/L for Gram-negative species, except for Pseudomonas aeruginosa, which had a cut-off value of 450 mg/L, consistent with earlier reports on the lack of activity of tigecycline against this species.
Conclusions: NRI offers an objective method for the analysis of MICs produced using Etests and the determination of epidemiological MIC cut-off values.
Keywords: antimicrobial susceptibility tests , MIC breakpoints , drug resistance , clinical microbiology , wild-type MIC distributions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J. Antimicrob. Chemother., November 1, 2008; 62(5): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Turnidge and D. L. Paterson Setting and Revising Antibacterial Susceptibility Breakpoints Clin. Microbiol. Rev., July 1, 2007; 20(3): 391 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Turnidge and G. Bordash Statistical Methods for Establishing Quality Control Ranges for Antibacterial Agents in Clinical and Laboratory Standards Institute Susceptibility Testing Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2483 - 2488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, J. M. Swenson, and H. S. Sader Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results for Acinetobacter spp. J. Clin. Microbiol., January 1, 2007; 45(1): 227 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Vahaboglu, F. Budak, M. Kasap, G. Gacar, S. Torol, A. Karadenizli, F. Kolayli, and C. Eroglu High prevalence of OXA-51-type class D {beta}-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres J. Antimicrob. Chemother., September 1, 2006; 58(3): 537 - 542. [Abstract] [Full Text] [PDF]
|
|